1 September 2024
Quarterly Cashflow Report - December 2010
Melbourne, Australia; Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) released today the Quarterly Cash Flow Report (Appendix 4C) for the quarter ended 31 December 2010.
The cash balance at 31 December 2010 was $19.7m compared to $22.8m at 30 June 2010.
The Operating & Investing cash outflow of $1.5m for the quarter includes costs of the phase 2 bacterial vaginosis (BV) program. Progress with the Phase 2 BV acute-treatment study for VivaGel®, which commenced in July 2010 has been pleasing, with 90% of patients (119 from a total of 132) now enrolled.
The December quarter result also includes financing cash flow proceeds of $1.2m from the exercise of share options.
Download ASX Announcement: Appendix 4C - December 2010 ( pdf file, 59kb)